In the BioHarmony Drug Report Database

"Preview" Icon

Gabapentin enacarbil

Horizant (gabapentin enacarbil) is a small molecule pharmaceutical. Gabapentin enacarbil was first approved as Horizant on 2011-04-06. It is used to treat bipolar disorder, epilepsy, partial epilepsies, phobic disorders, and postherpetic neuralgia in the USA. Horizant’s patents are valid until 2029-06-10 (FDA).

 

Trade Name

 

Horizant
 

Common Name

 

gabapentin enacarbil
 

ChEMBL ID

 

CHEMBL1628502
 

Indication

 

bipolar disorder, epilepsy, partial epilepsies, phobic disorders, postherpetic neuralgia
 

Drug Class

 

Gabamimetics

Image (chem structure or protein)

Gabapentin enacarbil structure rendering